Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951379 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone for Oral Premalignant Lesions
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT00951379: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00951379 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00951379, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how Actos (pioglitazone) may affect oral premalignant lesions (OPLs) and/or the risk of mouth cancer. The safety of this drug will also be studied.
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG Pioglitazone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951379
The ClinicalTrials.gov registry entry for NCT00951379 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00951379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951379 about?
NCT00951379 is a clinical study titled "Pioglitazone for Oral Premalignant Lesions". The goal of this clinical research study is to learn how Actos (pioglitazone) may affect oral premalignant lesions (OPLs) and/or the risk of mouth cancer. The safety of this drug will also be studied.
What is the current status of trial NCT00951379?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-02. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00951379?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), Pioglitazone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00951379?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.